• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Iopidine 0.5%
    / Lapidot

    Active Ingredient
    Apraclonidine (as HCl) 5 mg/ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Eye Drops

    5 ml

    not in the basket chart 9152 9085

    Related information


    Adults (including the elderly): One drop of IOPIDINE 5 mg/ml should be instilled into the affected eye(s) three times per day (t.i.d.). Since IOPIDINE 5 mg/ml will be used with other ocular glaucoma therapies, an approximate five minute interval between instillation of each medication should be observed to prevent washout of the previous dose. If, for any reason, the drop of IOPIDINE 5mg/ml does not remain in the eye, then the patient should repeat the dose by placing another drop in the eye. The maximum recommended duration of therapy is one month due to loss of effect over time (tachyphylaxis). However, some patients may benefit from treatment with IOPIDINE 5 mg/ml for longer periods.
    Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended.
    This may reduce the systemic absorption of medications administered via the ocular route and result in a decrease in systemic side effects.
    There are no special precautions for administration to the elderly.
    Children: Clinical studies to establish safety and efficacy in children have not been conducted and, therefore, IOPIDINE 5 mg/ml is not recommended for use in children under 12 years of age.


    IOPIDINE 5 mg/ml is indicated for short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery.
    The IOP lowering efficacy of IOPIDINE 5 mg/ml diminishes over time in most patients. Although some patients have received successful treatment with IOPIDINE 5 mg/ml for longer periods, the benefit for most patients is less than one month.
    The addition of IOPIDINE 5 mg/ml to patients already using two aqueous suppressing drugs (i.e. beta-blockers plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because IOPIDINE 5 mg/ml is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.


    IOPIDINE 5 mg/ml is contraindicated in children, in patients with a history of severe or unstable and uncontrolled cardiovascular disease, including severe uncontrolled arterial hypertension.
    IOPIDINE 5 mg/ml is contraindicated in patients with hypersensitivity to any component of the formulation or to systemic clonidine and in patients receiving monoamine oxidase inhibitors, systemic sympathomimetics or tricyclic antidepressants.